Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Take-home expansion: Scope and impact study (THESIS)

Award Number: R01DA057052
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Take-home expansion: Scope and impact study (THESIS) - Methadone is an effective treatment for opioid use disorder (OUD) that is delivered in the U.S. through specialized Opioid Treatment Programs (OTPs). Since the inception of the OTP system many decades ago, federal regulations have required frequent clinic attendance to monitor patients’ response to treatment and reduce the risks of methadone diversion. Patients could only ‘earn’ take-home methadone after significant time in treatment while demonstrating rigid standards for adherence and stability. However, these classic regulations were not grounded in strong empirical evidence. Recent regulatory changes transformed service delivery practices at OTPs. To reduce crowding in clinics, federal regulators swiftly issued exemptions that gave OTPs unprecedented discretion to provide take-home methadone. OTPs were suddenly permitted to dispense up to 14 days of take-home methadone for ‘less stable’ patients, and 28 days for ‘stable’ patients. More recently, the methadone regulations were permanently revised to allow even more flexibility and provider discretion. Research is needed to examine the scope and impact of these major changes to care delivery. This study will (1) characterize practice changes at OTPs during a period of regulatory change, (2) examine the relationship of expanded take-home methadone with patient outcomes, (3) develop a prediction model for safe receipt of take-home methadone, and (4) examine the relationship between expanded take-home methadone and methadone overdose deaths. The study will use clinical and administrative data from BayMark Health Services, one of the largest providers of methadone treatment in the U.S. This study will provide critical data for regulators, OTP administrators, and practitioners. It will yield highly novel data that could inform methadone treatment delivery over the next decade and beyond.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	4	4/1/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $633,988 )
2025	2025	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	4	7/23/2025	NON-COMPETING CONTINUATION	$633,988
														Subtotal = $633,988

Issue Date FY: 2024 ( Subtotal = $682,722 )
2024	2024	FRIENDS RESEARCH INSTITUTE, INC.	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	3	6/17/2024	NON-COMPETING CONTINUATION	$682,722
														Subtotal = $682,722

Issue Date FY: 2023 ( Subtotal = $628,884 )
2023	2023	FRIENDS RESEARCH INSTITUTE INC	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	2	6/29/2023	NON-COMPETING CONTINUATION	$628,884
2023	2022	FRIENDS RESEARCH INSTITUTE INC	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	1	12/23/2022	NEW	$0
														Subtotal = $628,884

Issue Date FY: 2022 ( Subtotal = $537,775 )
2022	2022	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	1	9/15/2022	NEW	$537,775
														Subtotal = $537,775

Grand Total All Awards = $2,483,369

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Take-home expansion: Scope and impact study (THESIS)

Award Number: R01DA057052

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer